Page last updated: 2024-12-05

2,3-dimethyl-1,4-naphthoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-dimethyl-1,4-naphthoquinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16615
CHEMBL ID354201
SCHEMBL ID571026
MeSH IDM0123081

Synonyms (35)

Synonym
2,3-dimethyl-1,4-naphthoquinone
nsc36460
wln: l66 bv evj c1 d1
usaf sn-29
2197-57-1
2,3-dimethylnaphthoquinone
nsc-36460
inchi=1/c12h10o2/c1-7-8(2)12(14)10-6-4-3-5-9(10)11(7)13/h3-6h,1-2h
ai3-16112
nsc 36460
brn 2044697
1,4-naphthoquinone, 2,3-dimethyl-
1,4-naphthalenedione, 2,3-dimethyl-
2,3-dimethylnaphthalene-1,4-dione
DB07669
HMS1666O12
CHEMBL354201
2,3-dimethyl-[1,4]naphthoquinone
2,3-dimethyl-1,4-dihydronaphthalene-1,4-dione
sy9io0b44o ,
unii-sy9io0b44o
2,3-dimethyl-naphthalene-1,4-dione
AKOS006239532
SCHEMBL571026
LGFDNUSAWCHVJN-UHFFFAOYSA-N
DTXSID50176380
2,3-dimethyl-(1,4)naphthoquinone
Q27096888
2,3-dimethyl-1,4-naphthalenedione
CAA19757
EN300-2637403
CS-0144641
PD005569
E87933
Z1198147654

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Modulation of DT-diaphorase activity in animals may therefore not only alter the severity of naphthoquinone toxicity, but also cause pronounced changes in the site of toxic action of these substances."( Effects of modulation of tissue activities of DT-diaphorase on the toxicity of 2,3-dimethyl-1,4-naphthoquinone to rats.
Munday, CM; Munday, R; Smith, BL, 2001
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID128409Compound was evaluated for anticancer activity against Sarcoma180 tumor bearing mice by measuring average weight (dose 15 mg/kg daily)1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
2,3-Dimethyl-1,4-naphthoquinone derivatives as bioreductive alkylating agents with cross-linking potential.
AID128411Compound was evaluated for anticancer activity against Sarcoma180 tumor bearing mice by measuring average weight (dose 3.25 mg/kg daily)1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
2,3-Dimethyl-1,4-naphthoquinone derivatives as bioreductive alkylating agents with cross-linking potential.
AID736844Neuroprotective activity in mouse HT22 cells assessed as prevention from glutamate-induced oxidative cell death by MTS assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.
AID736842Neurotoxicity in mouse HT22 cells assessed as cell viability after 24 hrs by MTS assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.
AID138172Compound was evaluated for anticancer activity against Sarcoma180 tumor bearing mice by measuring T/C X 100 (dose 3.25 mg/kg daily)1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
2,3-Dimethyl-1,4-naphthoquinone derivatives as bioreductive alkylating agents with cross-linking potential.
AID128413Compound was evaluated for anticancer activity against Sarcoma180 tumor bearing mice by measuring average weight (dose 7.5 mg/kg daily)1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
2,3-Dimethyl-1,4-naphthoquinone derivatives as bioreductive alkylating agents with cross-linking potential.
AID736843Therapeutic index, ratio of cytotoxic TC50 for mouse HT22 cells to neuroprotective PD50 for mouse HT22 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.
AID138174Compound was evaluated for anticancer activity against Sarcoma180 tumor bearing mice by measuring T/C X 100 (dose 7.5 mg/kg daily)1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
2,3-Dimethyl-1,4-naphthoquinone derivatives as bioreductive alkylating agents with cross-linking potential.
AID138170Compound was evaluated for anticancer activity against Sarcoma180 tumor bearing mice by measuring T/C X 100 (dose 15 mg/kg daily)1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
2,3-Dimethyl-1,4-naphthoquinone derivatives as bioreductive alkylating agents with cross-linking potential.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.49 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]